Listen to Gynecologic Oncology

Listen to the latest news from the experts in your field.

May 2023 Editor's Choice: Prioritizing and achieving diversity in clinical trial enrollment

Editor’s Choice Papers:  What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women Editorial:  Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approachHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Ann Oluloro, MD, MPH, University of WashingtonEloise Chapman-Davis, MD, Weill Cornell Medicine        

09-01
--:--

Beyond Anesthesia: Self-Hypnosis in ERAS Programs

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms

08-29
24:12

Carcinosarcoma Wars: A New Hope for TROP-2 Therapeutic Targeting

Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcoma Editorial: The search for new therapeutic options for uterine carcinosarcoma

07-14
20:25

To divert or not to divert: that is the question

Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs Editorial: Diverting ileostomy: An ounce of prevention, but when?

07-08
27:38

Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer

Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind? Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing: Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of AmericaRamez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CA

03-27
16:12

Prophylactic chemotherapy to prevent post-molar gestational trophoblastic disease - a long journey and a remarkable study

Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances?

03-03
18:12

Clinical trials: Panacea or pitfall

Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival Editorial: Clinical trials are not the solution to inequities in cancer care

01-27
30:47

FOLR1 status: Landscape beyond high grade serous ovarian cancer

Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma Editorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing: Tullia Rushton, MD Beryl L. Manning-Geist, MD

12-30
20:26

Benefits of hormonal therapy for low grade serous ovarian cancer

Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study Editorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief!

12-30
22:40

Implementation and impact of a financial navigation program in gynecologic oncology

Editor’s Choice: Implementation of a financial navigation program in gynecologic oncology Editorial: Financial toxicity: moving from describing the problem toward developing interventions Hosted by:Diane Yamada, MDFeaturing: Katharine M. Esselen, MDMargaret Liang, MD

10-23
32:25

LVSI in Stage 1 Endometrial Cancer

Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma Editorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment? Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing: Mohamed Elshaikh, MDBeriwal Sushil MD

09-25
18:19

Primary Surgery versus Radiotherapy for Inguinal Lymph Nodes in Vulvar Cancer

Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva Editorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring:  Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, Canada Dr Brenna Swift, MD, FRCSC, MSc, MASc, University of Toronto, Canada Dr Scott Glaser, MD, City of Hope, USA

09-02
31:59

Shifting trends and sicker patients - the future of gynecologic cancer

Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists Editorial: Who you gonna call? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmma Barber, MD, MS, Northwestern University Feinberg School of Medicine

07-12
14:49

2023 FIGO staging for endometrial cancer: a reappraisal on the path to continuous improvement

Reviews: 2023 changes to FIGO endometrial cancer staging: Counterpoint; 2023 FIGO staging system for endometrial cancer: The evolution of the revolution Editorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coin Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology  Featuring:  Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USA Dr. David Gaffney, MD-PhD, University of Utah, USA Dr. Mario Leitao, Jr., MD, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, USA

07-08
37:08

Editor's Choice: SENTIREC-endo study: Is the juice worth the squeeze?

Editor’s Choice Paper:Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study Editorial:Sentinel lymph node biopsy in high-risk endometrial cancer: The dénouement Hosted by:Gregg Nelson, MD, Social Media Editor of Gynecologic OncologyFeaturing:Sarah M. Bjørnholt, MD, Aarhus University Hospital, DenmarkSean Dowdy, MD, Mayo Clinic, USA

04-15
13:24

Editor's Choice: Caring for the Caregiver

Editor’s Choice Paper: Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers Editorial:The importance of family-focused care in the setting of advanced gynecological cancersHosted by:Sean Dowdy, MD, Associate Editor of Gynecologic OncologyFeaturing:Rachel A. Pozzar, PhD, RN, Dana Farber Cancer Institute and Harvard Medical SchoolAllison J. Applebaum, PhD, Caregivers Clinic, Memorial Sloan Kettering Cancer Center

04-04
19:40

Editor’s Choice: Lunchbox Trial

Editor’s Choice Paper: Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma Editorial:What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical CollegeGretchen Glaser, MD, Mayo Clinic John Weroha, MD, Mayo Clinic

02-29
10:18

Editor’s Choice: Engagement with ERAS patients leads to improved outcomes

Editor’s Choice Paper: Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients Editorial:How does mobile health engagement technology help gynecologic oncology patients recover from surgery, affect health equity, and impact healthcare costs?Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Teresa K.L. Boitano, MD, University of Alabama at BirminghamKevin M. Elias, MD, FACOG, FACS, Brigham and Women’s Hospital

01-29
10:18

October 2023 Editor’s Choice: OS updates for Imagyn50

Editor’s Choice Paper: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center 

11-17
14:03

September 2023 Editor’s Choice: Is now the time to begin thromboprophylaxis for all patients with advanced ovarian cancer, including those undergoing neoadjuvant chemotherapy?

Editor’s Choice Paper: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University 

10-27
16:40

Recommend Channels